{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:27:56Z","timestamp":1791167276189,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[1999,5,1]],"date-time":"1999-05-01T00:00:00Z","timestamp":925516800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[1999,5]]},"DOI":"10.1038\/8466","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T08:43:33Z","timestamp":1027673013000},"page":"582-585","source":"Crossref","is-referenced-by-count":408,"title":["Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity"],"prefix":"10.1038","volume":"5","author":[{"given":"Toufan","family":"Parman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Wiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[1999,5,1]]},"reference":[{"key":"BFnm0599582_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/tera.1420380303","volume":"38","author":"W Lenz","year":"1988","unstructured":"Lenz, W. A short history of thalidomide embryopathy. Teratology 38, 203\u201315 (1988).","journal-title":"Teratology"},{"key":"BFnm0599582_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/(SICI)1096-9926(199612)54:6<273::AID-TERA1>3.0.CO;2-#","volume":"54","author":"EE Castilla","year":"1996","unstructured":"Castilla, E.E. et al. Thalidomide, a current teratogen in South America. Teratology 54, 273\u20137 (1996).","journal-title":"Teratology"},{"key":"BFnm0599582_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/tera.1420380307","volume":"38","author":"TD Stephens","year":"1988","unstructured":"Stephens, T.D. Proposed mechanisms of action in thalidomide embryopathy. Teratology 38, 229\u201339 (1988).","journal-title":"Teratology"},{"key":"BFnm0599582_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10409239609110574","volume":"31","author":"PG Wells","year":"1996","unstructured":"Wells, P.G. & Winn, L.M. Biochemical toxicology of chemical teratogenesis. Crit. Rev. Biochem. Mol. Biol. 31, 1\u201340 (1996).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"BFnm0599582_CR5","doi-asserted-by":"publisher","first-page":"25079","DOI":"10.1074\/jbc.273.39.25079","volume":"273","author":"T Parman","year":"1998","unstructured":"Parman, T., Chen, G. & Wells, P.G. Free radical intermediates of phenytoin and related teratogens. Prostaglandin H synthase-catalyzed bioactivation, electron paramagnetic resonance spectrometry and photochemical product analysis. J. Biol. Chem. 273, 25079\u201388 (1998).","journal-title":"J. Biol. Chem."},{"key":"BFnm0599582_CR6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/0891-5849(95)00082-9","volume":"19","author":"L Liu","year":"1995","unstructured":"Liu, L. & Wells, P.G. DNA oxidation as a potential molecular mechanism mediating drug- induced birth defects: phenytoin and structurally related teratogens initiate the formation of 8-hydroxy-2'-deoxyguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues. Free Radic. Biol. Med. 19, 639\u201348 (1995).","journal-title":"Free Radic. Biol. Med."},{"key":"BFnm0599582_CR7","first-page":"A608","volume":"4","author":"RR Arlen","year":"1990","unstructured":"Arlen, R.R. & Wells, P.G. Extracellular thiol-disulfide status reflecting chemical toxicity mediated via oxidative stress: Validation with paraquat and t-butylhydroperoxide and implications for phenytoin and thalidomide teratogenicity. FASEB J. 4, A608 (1990).","journal-title":"FASEB J."},{"key":"BFnm0599582_CR8","first-page":"1649","volume":"277","author":"RR Arlen","year":"1996","unstructured":"Arlen, R.R. & Wells, P.G. Inhibition of thalidomide teratogenicity by acetylsalicylic acid: evidence for prostaglandin H synthase-catalyzed bioactivation of thalidomide to a teratogenic reactive intermediate. J. Pharm. Exp. Ther. 277, 1649\u201358 (1996).","journal-title":"J. Pharm. Exp. Ther."},{"key":"BFnm0599582_CR9","doi-asserted-by":"crossref","unstructured":"Wells, P.G., Kim, P.M., Nicol, C.J., Parman, T. & Winn, L.M. in Handbook of Experimental Pharmacology Vol. 124, Part I, Ch. 17 (eds. Kavlock, R.J. & Daston, G.P.) 453 \u2013518 (Springer-Verlag, Heidelberg, 1997).","DOI":"10.1007\/978-3-642-60445-4_17"},{"key":"BFnm0599582_CR10","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0891-5849(96)00340-1","volume":"22","author":"LM Winn","year":"1997","unstructured":"Winn, L.M. & Wells, P.G. Evidence for embryonic prostaglandin H synthase-catalyzed bioactivation and reactive oxygen species-mediated oxidation of cellular macromolecules in phenytoin and benzo[a]pyrene teratogenesis. Free Radic. Biol. Med. 22, 607\u2013 21 (1997).","journal-title":"Free Radic. Biol. Med."},{"key":"BFnm0599582_CR11","first-page":"172","volume":"49","author":"PM Kim","year":"1996","unstructured":"Kim, P.M. & Wells, P.G. Phenytoin-initiated hydroxyl radical formation: characterization by enhanced salicylate hydroxylation. Mol. Pharm. 49, 172\u201381 (1996).","journal-title":"Mol. Pharm."},{"key":"BFnm0599582_CR12","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0021-9258(18)48474-8","volume":"267","author":"KC Cheng","year":"1992","unstructured":"Cheng, K.C., Cahill, D.S., Kasai, H., Nishimura, S. & Loeb, L.A. 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G\u2014-T and A\u2014-C substitutions. J. Biol. Chem. 267, 166\u201372 (1992).","journal-title":"J. Biol. Chem."},{"key":"BFnm0599582_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0027-5107(97)00174-7","volume":"396","author":"J Ashby","year":"1997","unstructured":"Ashby, J. et al. Thalidomide: lack of mutagenic activity across phyla and genetic endpoints. Mutat. Res. 396, 45\u2013 46 (1997).","journal-title":"Mutat. Res."},{"key":"BFnm0599582_CR14","first-page":"338","volume":"25","author":"H Schumacher","year":"1965","unstructured":"Schumacher, H., Smith, R.L. & Williams, R.T. The metabolism of thalidomide: The fate of thalidomide and some of its hydrolysis products in various species. Br. J. Pharmacol. 25, 338\u2013351 (1965).","journal-title":"Br. J. Pharmacol."},{"key":"BFnm0599582_CR15","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1073\/pnas.78.4.2545","volume":"78","author":"GB Gordon","year":"1981","unstructured":"Gordon, G.B., Spielberg, S.P., Blake, D.A. & Balasubramanian, V. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc. Nat. Acad. Sci. USA 78, 2545\u2013 8 (1981).","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"BFnm0599582_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1520-6866(1997)17:1<1::AID-TCM2>3.0.CO;2-L","volume":"17","author":"PH Huang","year":"1997","unstructured":"Huang, P.H. & McBride, W.G. Interaction of [glutarimide-2-14C]-thalidomide with rat embryonic DNA in vivo [see comments]. Teratogen. Carcinogen. Mutagen. 17, 1\u20135 (1997).","journal-title":"Teratogen. Carcinogen. Mutagen."},{"key":"BFnm0599582_CR17","doi-asserted-by":"publisher","first-page":"i","DOI":"10.1002\/(SICI)1520-6866(1997)17:1<I::AID-TCM1>3.0.CO;2-L","volume":"17","author":"D Neubert","year":"1997","unstructured":"Neubert, D. Never-ending tales of the mode of the teratogenic action of thalidomide. Teratogen. Carcinogen. Mutagen. 17, i\u2013 ii (1997).","journal-title":"Teratogen. Carcinogen. Mutagen."},{"key":"BFnm0599582_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0041-008X(86)90449-7","volume":"82","author":"AG Braun","year":"1986","unstructured":"Braun, A.G., Harding, F.A. & Weinreb, S.L. Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450. Toxicol. Appl. Pharm. 82, 175\u20139 (1986).","journal-title":"Toxicol. Appl. Pharm."},{"key":"BFnm0599582_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0145-2126(91)90093-9","volume":"15","author":"SJ Hatfill","year":"1991","unstructured":"Hatfill, S.J., Fester, E.D., de Beer, D.P. & Bohm, L. Induction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites. Leukemia Res. 15, 129\u201336 (1991).","journal-title":"Leukemia Res."},{"key":"BFnm0599582_CR20","first-page":"521","volume":"9","author":"NA Jonsson","year":"1972","unstructured":"Jonsson, N.A. Chemical structure and teratogenic properties 3. A review of available data on structure-activity relationships and mechanism of action of thalidomide analogues. Acta Pharma. Suec. 9, 521\u2013 42 (1972).","journal-title":"Acta Pharma. Suec."},{"key":"BFnm0599582_CR21","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/BF02138700","volume":"24","author":"HM Wuest","year":"1968","unstructured":"Wuest, H.M., Fox, R.R. & Crary, D.D. Relationship between teratogenicity and structure in the thalidomide field. Experientia 24, 993\u2013 4 (1968).","journal-title":"Experientia"},{"key":"BFnm0599582_CR22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3109\/03602539409029800","volume":"26","author":"M Kitada","year":"1994","unstructured":"Kitada, M. & Kamataki, T. Cytochrome P450 in human fetal liver: significance and fetal- specific expression. Drug Metab. Rev. 26, 305\u201323 (1994).","journal-title":"Drug Metab. Rev."},{"key":"BFnm0599582_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/carcin\/11.2.321","volume":"11","author":"LH Pottenger","year":"1990","unstructured":"Pottenger, L.H. & Jefcoate, C.R. Characterization of a novel cytochrome P450 from the transformable cell line, C3H\/10T1\/2. Carcinogenesis 11, 321\u20137 (1990).","journal-title":"Carcinogenesis"},{"key":"BFnm0599582_CR24","first-page":"922","volume":"46","author":"HY Yang","year":"1994","unstructured":"Yang, H.Y., Lee, Q.P., Rettie, A.E. & Juchau, M.R. Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis. Mol. Pharmacol. 46, 922\u2013 8 (1994).","journal-title":"Mol. Pharmacol."},{"key":"BFnm0599582_CR25","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0891-5849(98)00193-2","volume":"26","author":"LM Winn","year":"1999","unstructured":"Winn, L.M. & Wells, P.G. Maternal administration of superoxide dismutase and catalase in phenytoin teratogenicity. Free Radic. Biol. Med. 26, 266\u201374 (1999).","journal-title":"Free Radic. Biol. Med."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm0599_582.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm0599_582","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm0599_582.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T22:43:52Z","timestamp":1684449832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm0599_582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1999,5]]}},"alternative-id":["BFnm0599582"],"URL":"https:\/\/doi.org\/10.1038\/8466","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,5]]}}}